The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.
 
Chau T. Dang
Consulting or Advisory Role - Daichii Sankyo; eviCore healthcare; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Fauzia Riaz
Research Funding - Genentech; Genentech (Inst)
 
Antoinette R. Tan
Consulting or Advisory Role - Abbvie; Athenex; Celgene; Eisai; G1 Therapeutics; Genentech/Roche; immunomedics; Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Arvinas (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Medscape
 
Katherine H. R. Tkaczuk
Consulting or Advisory Role - Amgen; Biocept
Research Funding - Abbott/AbbVie (Inst); Angiochem (Inst); AstraZeneca (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Infinite Biomedical (Inst); Menarini (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Puma Biotechnology (Inst); Seagen (Inst); TapImmune Inc. (Inst)
 
Anthony Francis Yu
Research Funding - Genentech; Genentech; Genentech (Inst)
 
Jennifer Liu
Consulting or Advisory Role - Bay Labs; Pfizer
 
Anita M. Fung
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Anna Yang
Employment - Genentech
Stock and Other Ownership Interests - Roche
Research Funding - Genentech; Genentech
 
Bann-mo Day
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Consulting or Advisory Role - Genentech
Research Funding - Genentech
Travel, Accommodations, Expenses - Genentech
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis
Consulting or Advisory Role - Napo Pharmaceuticals
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)